Phathom Pharmaceuticals, Inc.
corporate_fare Company Profile
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for PHAT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PHAT spans 8-K, 10-Q, 10-K, 424B5.
Recent high-impact activity:
- Phathom Q3 Revenue Jumps 71% to $84.7M; Second Straight Quarter of Positive Operating Cash Flow
- Q3 Revenue Jumps 71% to $84.7M as Phathom Turns Adjusted Profit, Reaffirms Guidance
- FDA Opens Comment Docket on VOQUEZNA Exclusivity Fight; Second ANDA Filer Emerges
- FDA Opens Public Docket on VOQUEZNA Exclusivity as ANDA Fight Escalates
- Generic Rival Sues FDA to Break VOQUEZNA Exclusivity Running to 2032
Financial Snapshot
Short Interest & Short Volume
4.83 days to coverFINRA reported short interest of 9,204,035 shares in PHAT as of the October 30, 2026 settlement, a 5.9% decrease from the prior period — about 4.8 days to cover at its recent average daily volume. On November 20, 2026, 52.9% of PHAT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.